BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $98.00 at Wells Fargo & Company

BridgeBio Pharma (NASDAQ:BBIO) had its target price boosted by Wells Fargo & Company from $88.00 to $98.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. JPMorgan Chase & Co. lifted their target price on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Morgan Stanley initiated coverage on shares of BridgeBio Pharma in a research report on Tuesday, January 6th. They set an “overweight” rating and a $96.00 price target on the stock. Cantor Fitzgerald increased their price target on BridgeBio Pharma from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Finally, TD Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Twenty-two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $81.55.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $75.25 on Friday. The business has a 50-day moving average of $75.60 and a 200-day moving average of $63.08. The company has a market capitalization of $14.50 billion, a price-to-earnings ratio of -18.00 and a beta of 1.13. BridgeBio Pharma has a 1 year low of $28.33 and a 1 year high of $84.94.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Thomas Trimarchi sold 16,934 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $66.46, for a total value of $1,125,433.64. Following the transaction, the chief financial officer owned 382,830 shares in the company, valued at approximately $25,442,881.80. This represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $74.26, for a total value of $148,520.00. Following the completion of the sale, the chief accounting officer directly owned 130,297 shares of the company’s stock, valued at $9,675,855.22. This trade represents a 1.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 300,700 shares of company stock worth $21,034,671. 18.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Large investors have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new stake in BridgeBio Pharma during the 4th quarter valued at $235,000. FORA Capital LLC grew its holdings in shares of BridgeBio Pharma by 62.2% during the fourth quarter. FORA Capital LLC now owns 18,035 shares of the company’s stock valued at $1,397,000 after buying an additional 6,919 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of BridgeBio Pharma by 3.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 1,975,315 shares of the company’s stock worth $151,012,000 after acquiring an additional 60,548 shares in the last quarter. Affinity Asset Advisors LLC increased its position in shares of BridgeBio Pharma by 392.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 320,000 shares of the company’s stock worth $24,477,000 after acquiring an additional 255,000 shares in the last quarter. Finally, Bridgewater Associates LP acquired a new stake in shares of BridgeBio Pharma in the 4th quarter worth about $3,302,000. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.